People: AcelRx Pharmaceuticals Inc (ACRX.O)

ACRX.O on Consolidated Issue listed on NASDAQ Global Market

3.50USD
29 May 2015
Change (% chg)

$0.05 (+1.45%)
Prev Close
$3.45
Open
$3.45
Day's High
$3.55
Day's Low
$3.44
Volume
552,758
Avg. Vol
814,992
52-wk High
$11.65
52-wk Low
$2.96

Search Stocks

Hamel, Lawrence 

Mr. Lawrence G. Hamel is the Chief Development Officer of AcelRx Pharmaceuticals Inc., since September 2006. From 1986 until September 2006, Mr. Hamel served as Product Development Manager, Director Project Management, Executive Director Oral Product Development, and Vice President Oral Products Development at ALZA Corporation. From 1977 until 1985, Mr. Hamel held a number of other positions at ALZA Corporation, including Senior Chemist, Research Scientist, and Senior Research Fellow. Mr. Hamel holds a B.S. in Biology from the University of Michigan.

Basic Compensation

Total Annual Compensation, USD 1,069,670
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 7,800
Fiscal Year Total, USD 1,077,470

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 31,680 315,589.00
Name Fiscal Year Total

Adrian Adams

--

Richard King

2,030,280

Howard Rosen

--

Timothy Morris

2,106,040

Pamela Palmer

1,661,310

Badri Dasu

1,079,640
As Of  30 Dec 2014
Search Stocks